EA201001771A1 - Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью - Google Patents

Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью

Info

Publication number
EA201001771A1
EA201001771A1 EA201001771A EA201001771A EA201001771A1 EA 201001771 A1 EA201001771 A1 EA 201001771A1 EA 201001771 A EA201001771 A EA 201001771A EA 201001771 A EA201001771 A EA 201001771A EA 201001771 A1 EA201001771 A1 EA 201001771A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
relaxin
acute
acute health
insufficiency
Prior art date
Application number
EA201001771A
Other languages
English (en)
Other versions
EA022948B1 (ru
Inventor
Элейн Унмори
Сэм Л. Тейчман
Гад Коттер
Деннис Р. Стьюарт
Марта Джо Вайтхаус
Original Assignee
Кортера, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кортера, Инк. filed Critical Кортера, Инк.
Publication of EA201001771A1 publication Critical patent/EA201001771A1/ru
Publication of EA022948B1 publication Critical patent/EA022948B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В заявке описаны способы снижения декомпенсации посредством острого вмешательства у индивидуумов, страдающих острой декомпенсированной сердечной недостаточностью. В частности, в заявке описаны способы лечения острой декомпенсации сердца путем введения релаксина в фармацевтически эффективном количестве.
EA201001771A 2008-05-16 2009-05-15 Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью EA022948B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27
PCT/US2009/044249 WO2009140659A2 (en) 2008-05-16 2009-05-15 Method of treating dyspnea associated with acute heart failure

Publications (2)

Publication Number Publication Date
EA201001771A1 true EA201001771A1 (ru) 2011-06-30
EA022948B1 EA022948B1 (ru) 2016-03-31

Family

ID=40834101

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201500552A EA201500552A1 (ru) 2008-05-16 2009-05-15 Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
EA201001771A EA022948B1 (ru) 2008-05-16 2009-05-15 Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201500552A EA201500552A1 (ru) 2008-05-16 2009-05-15 Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью

Country Status (30)

Country Link
US (7) US8053411B2 (ru)
EP (2) EP2829280A1 (ru)
JP (4) JP5651586B2 (ru)
CN (3) CN106177914A (ru)
AR (1) AR071810A1 (ru)
AU (1) AU2009246114B2 (ru)
BR (1) BRPI0913011A2 (ru)
CA (1) CA2724540C (ru)
CR (1) CR11749A (ru)
CY (1) CY1116925T1 (ru)
DK (1) DK2288373T3 (ru)
EA (2) EA201500552A1 (ru)
ES (1) ES2546287T3 (ru)
GB (2) GB2459983B (ru)
HK (5) HK1139051A1 (ru)
HR (1) HRP20150845T1 (ru)
HU (1) HUE025483T2 (ru)
IL (3) IL208992A (ru)
MA (1) MA32389B1 (ru)
MX (1) MX2010012450A (ru)
MY (2) MY159803A (ru)
NZ (3) NZ598709A (ru)
PL (1) PL2288373T3 (ru)
PT (1) PT2288373E (ru)
SG (2) SG10201609580YA (ru)
SI (1) SI2288373T1 (ru)
TW (1) TWI386202B (ru)
UA (1) UA99953C2 (ru)
WO (1) WO2009140659A2 (ru)
ZA (1) ZA201007449B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140657A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating chronic heart failure
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
RU2564900C2 (ru) * 2010-03-10 2015-10-10 Дзе Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. Модулирование аквапоринов релаксином
CA2802273A1 (en) * 2010-08-06 2012-02-09 Pronota N.V. Perlecan as a biomarker for renal dysfunction
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
ES2972902T3 (es) * 2010-08-17 2024-06-17 Ambrx Inc Polipéptidos de relaxina modificados y sus usos
KR20140054009A (ko) * 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
AU2013202269A1 (en) * 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
EP3311830A1 (en) * 2012-02-14 2018-04-25 The Regents of The University of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
ES2929283T3 (es) 2012-05-04 2022-11-28 Us Health Moduladores del receptor de relaxina 1
ES2671639T3 (es) 2012-10-26 2018-06-07 Chiesi Farmaceutici S.P.A. Métodos para controlar la presión arterial y reducir la disnea en la insuficiencia cardiaca
DK2981258T3 (da) 2013-04-05 2020-10-19 Scpharmaceuticals Inc Farmaceutiske formuleringer til subkutan indgivelse af furosemid
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
MA39320A1 (fr) * 2014-02-03 2018-04-30 Novartis Ag Filtres pour perfuseurs
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
EP3154559B1 (en) * 2014-06-13 2021-09-01 Novartis AG Use of serelaxin to reduce gdf-15
EP4011919A3 (en) 2015-12-09 2022-10-12 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
EP3413783A1 (en) 2016-02-12 2018-12-19 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
AU2018219283B2 (en) 2017-02-08 2022-05-19 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
KR20210150360A (ko) 2019-01-31 2021-12-10 에스씨파마슈티칼스 인코포레이티드 푸로세미드의 농축된 액체 제약 제제 및 그의 투여 방법
WO2024047130A1 (en) 2022-08-31 2024-03-07 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5478807A (en) 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
EP0707650B1 (en) 1993-06-21 2003-05-21 Genentech, Inc. Process for producing human relaxin
WO1995003822A2 (en) 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
CA2229479C (en) 1995-08-15 2010-03-30 Connective Therapeutics, Inc. Method of promoting angiogenesis
EP1253929B1 (en) 2000-02-09 2007-05-23 BAS Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
KR100749857B1 (ko) 2004-03-30 2007-08-16 연세대학교 산학협력단 릴랙신 유전자를 포함하는 유전자 전달 시스템 및 릴랙신을이용한 약제학적 조성물
US20060264367A1 (en) * 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
WO2007008907A2 (en) 2005-07-11 2007-01-18 Abbott Laboratories Methods for determining how to treat congestive heart failure
WO2009007848A2 (en) 2007-07-12 2009-01-15 Compugen Ltd. Bioactive peptides and method of using same
WO2009140657A2 (en) 2008-05-16 2009-11-19 Corthera, Inc. Method of treating chronic heart failure
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin

Also Published As

Publication number Publication date
JP5875646B2 (ja) 2016-03-02
GB2462221A (en) 2010-02-03
US20100048475A1 (en) 2010-02-25
US20120040902A1 (en) 2012-02-16
HK1151229A1 (en) 2012-01-27
US8053411B2 (en) 2011-11-08
US20130210730A1 (en) 2013-08-15
US20150320834A1 (en) 2015-11-12
IL208992A0 (en) 2011-01-31
AR071810A1 (es) 2010-07-14
PT2288373E (pt) 2015-10-19
SG191587A1 (en) 2013-07-31
GB2459983A (en) 2009-11-18
JP2015013870A (ja) 2015-01-22
PL2288373T3 (pl) 2015-11-30
AU2009246114A1 (en) 2009-11-19
US9205132B2 (en) 2015-12-08
GB0908432D0 (en) 2009-06-24
US9579363B2 (en) 2017-02-28
US8415301B2 (en) 2013-04-09
JP2013040174A (ja) 2013-02-28
JP2016053040A (ja) 2016-04-14
CN106177914A (zh) 2016-12-07
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
US9066916B2 (en) 2015-06-30
CA2724540A1 (en) 2009-11-19
GB2462221B (en) 2010-09-01
MY159803A (en) 2017-02-15
BRPI0913011A2 (pt) 2019-09-03
JP2011520918A (ja) 2011-07-21
CN103212063A (zh) 2013-07-24
EA201500552A1 (ru) 2016-07-29
DK2288373T3 (en) 2015-09-28
CA2724540C (en) 2014-07-08
HRP20150845T1 (hr) 2015-11-06
JP5638044B2 (ja) 2014-12-10
EA022948B1 (ru) 2016-03-31
CN102036679A (zh) 2011-04-27
EP2829280A1 (en) 2015-01-28
UA99953C2 (ru) 2012-10-25
WO2009140659A2 (en) 2009-11-19
IL228244A (en) 2016-10-31
HK1140693A1 (en) 2010-10-22
GB2459983B (en) 2010-04-28
IL208992A (en) 2013-09-30
HK1139051A1 (en) 2010-09-10
TWI386202B (zh) 2013-02-21
ES2546287T3 (es) 2015-09-22
ZA201007449B (en) 2011-06-29
AU2009246114B2 (en) 2013-01-31
IL247351A0 (en) 2016-09-29
MY158327A (en) 2016-09-30
EP2288373A2 (en) 2011-03-02
WO2009140659A3 (en) 2010-07-22
CN103212063B (zh) 2015-07-22
TW200948353A (en) 2009-12-01
EP2288373B1 (en) 2015-06-24
US20130116181A1 (en) 2013-05-09
HK1187550A1 (zh) 2014-04-11
CR11749A (es) 2011-02-11
HUE025483T2 (en) 2016-02-29
US8372809B2 (en) 2013-02-12
US20170151311A1 (en) 2017-06-01
MX2010012450A (es) 2011-03-21
NZ598709A (en) 2013-09-27
SI2288373T1 (sl) 2015-12-31
SG10201609580YA (en) 2016-12-29
NZ701038A (en) 2016-01-29
CY1116925T1 (el) 2017-04-05
JP5651586B2 (ja) 2015-01-14
US20120040903A1 (en) 2012-02-16
HK1202054A1 (en) 2015-09-18
GB0918132D0 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
EA201001771A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
MX2010000937A (es) Tratamiento del trastorno por estrés postraumático.
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
CR20110552A (es) Tratamiento de transtornos resistentes a la insulina
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
MX2015005548A (es) Tratamiento de cancer con pomalidomida en un individuo con daño renal.
MX2011009804A (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.
MX2010006443A (es) TRATAMIENTO DE CARDIOPATIAS USANDO ß-BLOQUEANTES.
WO2008019388A3 (en) Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
WO2010048264A3 (en) Methods and compositions for the treatment of immunoinflammatory disorders
AU2016219717A1 (en) Treating dyspnea associated with acute heart failure with relaxin
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
UA44395U (ru) Применение тиоцетама в качестве диуретического средства с мягким мочегонным действием в комплексном лечении
AU2013201629B2 (en) Treating dyspnea associated with acute heart failure with relaxin
TN2010000504A1 (en) Treating dyspnea associated with acute heart failure with relaxin
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
RU2011148536A (ru) Способ комплексного лечения острой кишечной непроходимости карциноматозного генеза
RU2007140029A (ru) Способ лечения хронической сердечной недостаточности
RU2008130241A (ru) Способ и средство для реабилитации детей с хроническими риносинуситами
UA36369U (ru) Способ лечения артериальной гипертензии на санаторно-курортном этапе
UA34796U (ru) Способ коррекции состояния макрофагальной системы у больных с синдромом повышенной утомляемости

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ KG TJ RU